Selected Publications
Zhang, Y, Kim KH, Yoon DH, Patel, R.P., Jo JC, Cho H, Lee JH, Lee HJ, Cui LG, Hwang IS, Lee YH, Kim JH, Lee YG, Guruprasad P, Lee JS, Chung J, Ruella M: CT130/18 An open label, does escalation, phase 1 study of AT101, a novel CD10-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma. AACR Annual Meeting : 2023.
Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J, Ha H, Haug-Kroeper M, Doray B, Gill S, Ruella M, Hayer KE, Weitzman MD, Green AM, Fluhrer R, Singh N.: Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nat Commun. 11 (13(1)): 3367,2022 .
Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni, K, Ghilrardi G, Lee, YG, Frey N, Scholler J, Gabunia K, Wu G, Chong, E, Porter, D.L., June, C, Schuster S.J., Bhoj, V, Facciabene, A: Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects Journal for Immunotherapy of Cancer (JITC) 10 : 2022.
Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M.: Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer Cancer Discov : 2022.
Ascierto PA, Avallone A, Bhardwaj N, Bifulco C, Bracarda S, Brody JD, Buonaguro L, Demaria S, Emens LA, Ferris RL, Galon J, Khleif SN, Klebanoff CA, Laskowski T, Melero I, Paulos CM, Pignata S, Ruella M, Svane IM, Taube JM, Fox BA, Hwu P, Puzanov I.: Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd. J Transl Med : 2022.
Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, Landsburg JD, Gerson JN, Barta SK, Pajarillo R, Myers J, Chen AI, Schachter L, Yelton R, Ballard HJ, Hodges Dwinal A, Gier S, Victoriano D, Weber E, Napier E, Garfall A, Porter DL, Jäger U, Maziarz RT, Ruella M*, Schuster SJ*.: Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas. Ann Oncol : 2022.
Aznar M.A., Good C.R., Kuramitsu S, Samareh P, AgarwaL S, Donahue G, Ishiyama K, Wellhausen N, Rennels A.K., Ma Y, Tian L, Guedan S, Alexander K.A., Zhang Z, Rommel P.C., Singh N, Glastad K.M., Richardson M.W., Watanabe K, Tanyi J.L., O’Hara M.H., Ruella M, Lacey S.F., Moon E.K., Schuster S.J., Albelda S.M., Lanier L.L., Young R.M., Berger S.L., June C.H.: Mechanisms of CAR T cell dysfunction and identification of transcription factors that drive the exhaustion phenotype Cancer Research 82 : 2022.
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M.: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy Nat Med 28 (4): 713-723,2022.
Nasta SD, Hughes ME, Namoglu EC, Garfall A, DiFilippo H, Ballard HJ, Barta SK, Chong EA, Frey NV, Gerson JN, Landsburg DJ, Ruella M, Schuster SJ, Svoboda J, Weber E, Porter DL.: Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. Clin Lymphoma Myeloma Leuk. 8 : e730-e737,2022.
46., Gill SI, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov MA, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Blood Adv. 2022 Mar 29:bloodadvances.2022007317. doi: 10.1182/bloodadvances.2022007317. Epub ahead of print. PMID: 35349631.: Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Advances 8 (6(21)): 5774-5785,2022.
View all publications
Academic Contact Information
South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia,
PA
191004
Phone: 215-746-4880